{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:11:00Z","timestamp":1789603860478,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023JJ40929"],"award-info":[{"award-number":["2023JJ40929"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2025JJ50599"],"award-info":[{"award-number":["2025JJ50599"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["CX20250432"],"award-info":[{"award-number":["CX20250432"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170640"],"award-info":[{"award-number":["82170640"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302539"],"award-info":[{"award-number":["82302539"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ijid.2026.108370","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:49:48Z","timestamp":1767631788000},"page":"108370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Anti-interferon-\u03b1 antibodies and HBsAg seroclearance during peginterferon-\u03b1 therapy in chronic hepatitis B"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2022-5242","authenticated-orcid":false,"given":"Chuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feilan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108370_bib0001","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1016\/S1473-3099(24)00307-4","article-title":"WHO\u2019s 2024 global hepatitis report","volume":"24","author":"Burki","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108370_bib0002","first-page":"3","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (2022 version)","volume":"41","author":"You","year":"2023","journal-title":"Chin J Infect Dis"},{"key":"10.1016\/j.ijid.2026.108370_bib0003","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2026.108370_bib0004","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ijid.2026.108370_bib0005","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/hep.27323","article-title":"Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections","volume":"61","author":"Rehermann","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ijid.2026.108370_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.733364","article-title":"Interferon and hepatitis B: current and future perspectives","volume":"12","author":"Ye","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijid.2026.108370_bib0007","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/HEP.0000000000000524","article-title":"Single-cell RNA sequencing reveals the immunoregulatory roles of PegIFN-\u03b1 in patients with chronic hepatitis B","volume":"79","author":"Jiang","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.ijid.2026.108370_bib0008","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2018.01.034","article-title":"Hepatitis B virus does not interfere with innate immune responses in the human liver","volume":"154","author":"Suslov","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijid.2026.108370_bib0009","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00535-022-01890-8","article-title":"Immune therapies against chronic hepatitis B","volume":"57","author":"Akbar","year":"2022","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ijid.2026.108370_bib0010","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jvh.13283","article-title":"The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: a systematic review and meta-analysis","volume":"27","author":"Fonseca","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ijid.2026.108370_bib0011","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1007\/s12072-024-10666-6","article-title":"Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis","volume":"18","author":"Zhang","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ijid.2026.108370_bib0012","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108370_bib0013","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ijid.2026.108370_bib0014","article-title":"Suppression of interferon-\u03b1 treatment response by host negative factors in hepatitis B virus infection","volume":"8","author":"Wang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ijid.2026.108370_bib0015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/hep.32400","article-title":"Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B","volume":"76","author":"Perrillo","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ijid.2026.108370_bib0016","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/HEP.0000000000000878","article-title":"Neutralizing antibodies to interferon alfa arising during peginterferon therapy of chronic hepatitis B in children and adults: results from the HBRN Trials","volume":"81","author":"Zahoor","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.ijid.2026.108370_bib0017","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1046\/j.1365-2141.1996.d01-1790.x","article-title":"Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha","volume":"94","author":"Russo","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijid.2026.108370_bib0018","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(03)14541-2","article-title":"Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis","volume":"362","author":"Sorensen","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2026.108370_bib0019","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1365-2893.2012.01598.x","article-title":"Anti-interferon-\u03b1 neutralizing antibody is associated with nonresponse to pegylated interferon-\u03b1 plus ribavirin in chronic hepatitis C","volume":"19","author":"Matsuda","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ijid.2026.108370_bib0020","first-page":"287","article-title":"Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2","volume":"45","author":"Stancek","year":"2001","journal-title":"Acta Virol"},{"key":"10.1016\/j.ijid.2026.108370_bib0021","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3851\/IMP2711","article-title":"Presence of anti-interferon antibodies is not associated with non-response to pegylated interferon treatment in chronic hepatitis B","volume":"19","author":"Arends","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijid.2026.108370_bib0022","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0168-8278(89)90034-2","article-title":"Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon","volume":"8","author":"Porres","year":"1989","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2026.108370_bib0023","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/hep.1840120603","article-title":"Interferon antibodies may negate the antiviral effects of recombinant \u03b1-interferon treatment in patients with chronic hepatitis B virus infection","volume":"12","author":"Lok","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.ijid.2026.108370_bib0024","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/gut.30.8.1116","article-title":"Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response","volume":"30","author":"Brook","year":"1989","journal-title":"Gut"},{"key":"10.1016\/j.ijid.2026.108370_bib0025","doi-asserted-by":"crossref","first-page":"101382","DOI":"10.1016\/j.jhepr.2025.101382","article-title":"Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFN\u03b1 non-response","volume":"7","author":"Fink","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ijid.2026.108370_bib0026","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2026.108370_bib0027","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/jvh.13599","article-title":"Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance \u2013 suggesting a valuable endpoint for early development HBV trials","volume":"28","author":"De Ridder","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ijid.2026.108370_bib0028","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/apt.15098","article-title":"Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B","volume":"49","author":"Liem","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ijid.2026.108370_bib0029","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","article-title":"End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB","volume":"77","author":"Huang","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2026.108370_bib0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.critrevonc.2010.06.012","article-title":"Immunosenescence and cancer","volume":"75","author":"Pawelec","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijid.2026.108370_bib0031","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1615\/CritRevOncog.2013010591","article-title":"Optimization of immunotherapy in elderly cancer patients","volume":"18","author":"Tomihara","year":"2013","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.ijid.2026.108370_bib0032","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12072-021-10153-2","article-title":"High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B","volume":"15","author":"Duan","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ijid.2026.108370_bib0033","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/hep4.1859","article-title":"Presence of liver inflammation in Asian patients with chronic Hepatitis B with normal ALT and detectable HBV DNA in absence of liver fibrosis","volume":"6","author":"Liu","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ijid.2026.108370_bib0034","doi-asserted-by":"crossref","first-page":"eaan0241","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijid.2026.108370_bib0035","doi-asserted-by":"crossref","first-page":"eaba6322","DOI":"10.1126\/scitranslmed.aba6322","article-title":"Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection","volume":"13","author":"Nishio","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijid.2026.108370_bib0036","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","article-title":"Structure and function of immunoglobulins","volume":"125","author":"Schroeder","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ijid.2026.108370_bib0037","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3389\/fimmu.2018.02061","article-title":"The dual nature of type I and type II interferons","volume":"9","author":"Lee","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijid.2026.108370_bib0038","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/biomedicines13020299","article-title":"Anti-drug antibody response to therapeutic antibodies and potential mitigation strategies","volume":"13","author":"Howard","year":"2025","journal-title":"Biomedicines"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226000056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226000056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:53:36Z","timestamp":1784548416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226000056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":38,"alternative-id":["S1201971226000056"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108370","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-interferon-\u03b1 antibodies and HBsAg seroclearance during peginterferon-\u03b1 therapy in chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108370"}}